GRI Bio Inc (GRI)

Currency in USD
1.390
-0.050(-3.47%)
Closed·
1.440+0.050(+3.60%)
·
GRI Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
GRI is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.3901.450
52 wk Range
1.10030.430
Key Statistics
Prev. Close
1.44
Open
1.41
Day's Range
1.39-1.45
52 wk Range
1.1-30.43
Volume
50.02K
Average Volume (3m)
246.7K
1-Year Change
-82.97%
Book Value / Share
1.42
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
GRI Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
22.000
Upside
+1,482.73%
Members' Sentiments
Bearish
Bullish
ProTips
2 analysts have revised their earnings downwards for the upcoming period

GRI Bio Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Buy
Moving Averages
Sell

GRI Bio Inc Company Profile

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company’s portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

Compare GRI to Peers and Sector

Metrics to compare
GRI
Peers
Sector
Relationship
P/E Ratio
−0.3x−1.5x−0.5x
PEG Ratio
-−0.080.00
Price/Book
1.0x1.1x2.6x
Price / LTM Sales
-20.5x3.3x
Upside (Analyst Target)
-300.2%40.3%
Fair Value Upside
Unlock13.4%5.1%Unlock

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 22.000
(+1,482.73% Upside)

Earnings

Latest Release
May 15, 2025
EPS / Forecast
-5.80 / -0.24
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

GRI Income Statement

People Also Watch

0.394
ADIL
-0.25%
21.81
SRPT
+7.44%
2.53
INMB
+3.27%
0.512
WINT
-0.77%
0.617
PMN
-2.06%

FAQ

What Stock Exchange Does GRI Bio Trade On?

GRI Bio is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for GRI Bio?

The stock symbol for GRI Bio is "GRI."

What Is the GRI Bio Market Cap?

As of today, GRI Bio market cap is 3.47M.

What Is GRI Bio's Earnings Per Share (TTM)?

The GRI Bio EPS (TTM) is -36.38.

From a Technical Analysis Perspective, Is GRI a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

How Many Times Has GRI Bio Stock Split?

GRI Bio has split 4 times.

How Many Employees Does GRI Bio Have?

GRI Bio has 4 employees.

What is the current trading status of GRI Bio (GRI)?

As of 16 Aug 2025, GRI Bio (GRI) is trading at a price of 1.39, with a previous close of 1.44. The stock has fluctuated within a day range of 1.39 to 1.45, while its 52-week range spans from 1.10 to 30.43.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.